Wake Forest University Health Sciences

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Wake Forest University Health Sciences sits in the top decile of US sponsors by registered trial count (#27 of 15,742 sponsors by registered trial count).

1,140 total trials 174 currently recruiting 724 completed early-phase tilt top decile by trial count

Wake Forest University Health Sciences: 1,140 sponsored US clinical trials, 174 recruiting.

Wake Forest University Health Sciences sponsors 1,140 registered US clinical trials on ClinicalTrials.gov, 174 of them currently recruiting, and 724 completed. 111 of these trials are in Phase 3-4 (later-stage) and 239 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 9 trials.

Top-decile sponsor footprint

Wake Forest University Health Sciences ranks in the top decile of sponsors by registered trial count (#27 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 44/100

724 of 885 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,140 total, page 12 of 23

COMPLETED NA

Retropubic vs. Single-Incision Mid-Urethral Sling for Stress Urinary Incontinence

NCT03520114

COMPLETED

Supportive Care Service Availability for Cancer Caregivers in Community Oncology Practices

NCT03746314

COMPLETED NA

Supportive Programs for Supporting Optimal Recovery in Participants Undergoing Gynecological Surgery

NCT03681405

COMPLETED

FGF23 and Angiotensin-(1-7) in Hypophosphatemia (GAP)

NCT03489993

COMPLETED

Pediatric Primary Hypertension and the Renin-Angiotensin System (PHRAS)

NCT03310684

COMPLETED Phase 1

Efficacy of Lidocaine Gel Enema After Endoscopic Hemorrhoid Band Ligation for Relief of Post Procedural Pain

NCT03797703

COMPLETED NA

Study of the Effects of HIRREM-SOP for Insomnia

NCT03607994

TERMINATED Phase 2

Subsequent Line Gemcitabine and Nivolumab in Treating Participants With Metastatic Small Cell Lung Cancer

NCT03662074

COMPLETED NA

Integrated Multidisciplinary Patient and Family Advance Care Planning Trial

NCT03609658

COMPLETED NA

Anchorsure Versus Capio for Sacrospinous Ligament Fixation

NCT03565640

TERMINATED

Identifying Novel Aging Targets for Treatment of Delirium

NCT03682874

COMPLETED

Short-term Clinical Deterioration After Acute Pulmonary Embolism

NCT03915925

COMPLETED Phase 4

Chewed Versus Integral Pill of Ticagrelor

NCT03708588

COMPLETED NA

Graft-first Versus Fistula-first in Older Patients With End-stage Kidney Disease

NCT03545113

TERMINATED NA

Infiltration Effect on SUV

NCT03320564

COMPLETED

Pain and Sensation After Regional Anesthesia - Pilot Study

NCT03623035

TERMINATED

Developing and Validating Fertilit-e

NCT03599661

TERMINATED

Adaptation of an eHealth (Web-application) Platform for Delivery of a Sedentary Behavior Intervention Among Prostate Cancer Patients

NCT03740035

COMPLETED NA

HIRREM for Stage 1 Primary Hypertension

NCT03479697

COMPLETED NA

A Mobile Intervention to Reduce Pain and Improve Health (MORPH)

NCT03377634

COMPLETED NA

Project 2 Cigarette and E-cigarette Nicotine Content and E-liquid Flavors

NCT03185546

COMPLETED NA

Acupuncture in Reducing Chemotherapy-Induced Peripheral Neuropathy in Participants With Stage I-III Breast Cancer

NCT03505671

COMPLETED Phase 4

Extended Release Local Anesthetic for Postsurgical Pain After Posterior Colporrhaphy and Perineorrhaphy

NCT03875664

COMPLETED

Brain Networks and Mobility Function: B-NET

NCT03430427

COMPLETED NA

Stepped-Care Telehealth for Distress in Cancer Survivors

NCT03060096

TERMINATED

Influence of Contrast Injection Force on the Accuracy of Vessel Measurements in Cerebral Angiography

NCT03949023

COMPLETED

Prepulse Inhibition in Youth Contact Sports Players

NCT04058184

COMPLETED

Clinical vs. Anecdotal Evidence - Pediatric Atopic Dermatitis

NCT03559075

COMPLETED

Stress Test in Detecting Heart Damage in Premenopausal Women With Stage I-III Breast Cancer

NCT03505736

COMPLETED NA

Habitual Diet and Avocado Trial

NCT03528031

COMPLETED Phase 4

Weight Loss With Risedronate for Bone Health

NCT03411902

COMPLETED Phase 4

The Use Of Liposomal Bupivacaine For Pain Control

NCT03722927

TERMINATED NA

Learning by Repetitive Viewing of Peer Modeling Patient Education Videos by Adults With Down Syndrome

NCT03551418

COMPLETED Phase 4

Pre-medication With Alfentanil vs Placebo During ECT

NCT03359395

COMPLETED NA

Implementation of Smoking Cessation Within NCI Community Oncology Research Program (NCORP) Sites

NCT03291587

COMPLETED NA

HIRREM Hot Flashes Study

NCT03512002

COMPLETED NA

Systems Support Mapping in Guiding Self-Management in Stage I-III Colorectal Cancer Survivors

NCT03520283

COMPLETED

Hidradenitis Suppurativa Mail Survey

NCT03572738

COMPLETED NA

A Priming Intervention to Increase Patient Willingness to Use Injectables for the Management of Psoriasis

NCT03465696

COMPLETED NA

RAVE: Radial Artery Vascular Complication and Resource Utilization

NCT03522077

COMPLETED Phase 4

Anxiety and Depression in Epilepsy: A Treatment Study

NCT03464383

COMPLETED

Prehospital Translation of Chest Pain Tools

NCT03494556

TERMINATED NA

MucoLox Formulation to Mitigate Mucositis Symptoms in Head/Neck Cancer

NCT03461354

COMPLETED NA

EHealth Mindful Movement and Breathing in Improving Outcomes in Participants Undergoing Gynecologic Surgery

NCT03379376

COMPLETED Phase 1

Feasibility of Aromatherapy in an Awake Craniotomy Environment

NCT03328143

TERMINATED Phase 2

Docusate/Senna for the Treatment of Diabetic Gastroparesis

NCT03342157

COMPLETED NA

Independent Weight Loss Maintenance for Communities With Arthritis in North Carolina: the I-CAN Clinical Trial

NCT03832296

TERMINATED Phase 2

Disulfiram and Copper Gluconate With Temozolomide in Unmethylated Glioblastoma Multiforme

NCT03363659

COMPLETED NA

Topical Keratin in Treating Radiation Dermatitis in Patients With Breast Cancer

NCT03374995

COMPLETED NA

Targeting Obesity to Optimize Health in Cardiac Rehab (TOPCARE)

NCT03423238

← Previous Page 12 of 23 Next →

Phase Distribution

PhaseTrial count
Phase 1 96
Phase 2 143
Phase 3 31
Phase 4 80

What is open in the Wake Forest University Health Sciences pipeline

174 recruiting of 1,140 indexed (15% open); 724 completed (64%).

Phase mix: 111 late (III/IV) vs 239 early (I/II) (early-phase heavy).

Top condition: Breast Cancer (9 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Wake Forest University Health Sciences: open-pipeline peers nationwide

Peers matched on 1,140 registered trials and 15% open enrollment, not the therapeutic-area sidebar.

Wake Forest University Health Sciences sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 8%10%12%14%16%18%20% Total trials Recruiting share Wake Forest University Health SciencesUniversity of Alabama at BirminghamNYU Langone HealthUniversity of North Carolina, Chapel HillUniversity of FloridaBaylor UniversityCornell UniversityArrowhead Regional Medical CenterAurinia Pharmaceuticals
Wake Forest University Health Sciences sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Wake Forest University Health Sciences sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,140 trials (± recruiting share)

Sponsors near 15% open enrollment (± trial volume)

What to do with this Wake Forest University Health Sciences page

1,140 registered trials is a research-attention snapshot, not an endorsement of Wake Forest University Health Sciences or any single study.

  • 174 of Wake Forest University Health Sciences's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Breast Cancer is the condition Wake Forest University Health Sciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Wake Forest University Health Sciences pipeline card: 1,140 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.